2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1902

Utility of Glyca, a Novel Inflammatory Marker, for Assessment of Rheumatoid Arthritis Disease Activity
Abstract Number: 1104

Utility of the 2010 ACR Diagnostic Criteria for Fibromyalgia for Pediatric Patients with Juvenile Fibromyalgia
Abstract Number: 2533

Utility of the American-European Consensus Group and American College of Rheumatology Classification Criteria for Sjögren’s Syndrome in Patients with Systemic Autoimmune Diseases in the Clinical Setting
Abstract Number: 1446

Utility of Ultrasound in the Nuffield Orthopaedic Centre Emergency Rheumatology Clinic: Survey of Clinical Effectiveness
Abstract Number: 191

Utilization and Outcomes Following Total Shoulder Arthroplasty in Elderly and Non-Elderly Patients
Abstract Number: 1669

Validation of a Machine Learning Lupus Nephritis Decision Support Tool to Predict Complete Response to Therapy
Abstract Number: 1896

Validation of a Novel IFN-Regulated Gene Score As Biomarker in Chronic Atypical Neutrophilic Dermatosis with Lipdoystrophy and Elevated Temperature (CANDLE) Patients on Baricitinib, a Janus Kinase 1 /2 Inhibitor, a Proof of Concept
Abstract Number: 385

Validation of a Prognostic Model to Predict Structural Damage Assessed By X-Ray in Patients with RA Using MRI Data from a Clinical Trial
Abstract Number: 2570

Validation of Modified Disease Activity and Functional Status Questionnaires in Spondyloarthritis
Abstract Number: 2769

Validation of New 2012 EULAR/ACR Classification Criteria for Polymyalgia Rheumatica: Comparison with the Previous Criteria in a Prospective Multi-Center Study
Abstract Number: 369

Validation of Snapshot, a Rheumatoid Arthritis Assessment Tool, Against CDAI, DAS28 (ESR), and DAS28 (CRP) in Canadian Patients with Rheumatoid Arthritis
Abstract Number: 55

Validation of the Diagnosis of Avascular Necrosis of Bone in Administrative Data
Abstract Number: 261

Validation of the Dutch-Flemish Promis Pain Behavior and Pain Interference Item Banks in Patients with Chronic Pain
Abstract Number: 260

Validation of the Dutch-Flemish Promis Physical Functioning Item Bank in Patients with Chronic Pain
Abstract Number: 1183

Validation of the Omeract Psoriatic Arthritis Magnetic Resonance Imaging Score for the Hand and Foot in a Randomized Placebo-Controlled Trial

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].